The estimated Net Worth of John A Iii Stalfort is at least $2.32 million dollars as of 16 August 2023. John Stalfort owns over 777,778 units of Taysha Gene Therapies stock worth over $2,318,564 and over the last 6 years John sold TSHA stock worth over $0.
John has made over 5 trades of the Taysha Gene Therapies stock since 2018, according to the Form 4 filled with the SEC. Most recently John bought 777,778 units of TSHA stock worth $700,000 on 16 August 2023.
The largest trade John's ever made was buying 777,778 units of Taysha Gene Therapies stock on 16 August 2023 worth over $700,000. On average, John trades about 135,918 units every 212 days since 2018. As of 16 August 2023 John still owns at least 999,381 units of Taysha Gene Therapies stock.
You can see the complete history of John Stalfort stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247.
Over the last 4 years, insiders at Taysha Gene Therapies have traded over $3,159,500 worth of Taysha Gene Therapies stock and bought 21,030,825 units worth $24,949,013 . The most active insiders traders include Paul B Manning, John A Iii Stalfort et R.A. Ii Session. On average, Taysha Gene Therapies executives and independent directors trade stock every 44 days with the average trade being worth of $1,947,009. The most recent stock trade was executed by Paul B Manning on 27 June 2024, trading 1,333,333 units of TSHA stock currently worth $2,999,999.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Taysha Gene Therapies executives and other stock owners filed with the SEC include: